華雅旗下紅榮微再授權(quán)代理（上海）TAKARA CellArtis，Rubicon產(chǎn)品 

1500 1904 520 紅榮微再-客服: 經(jīng)銷商專員

產(chǎn)品圖片僅供參考。實際產(chǎn)品包括細胞株+培養(yǎng)基+添加劑+包被劑

人iPS誘導(dǎo)多能干細胞

(Human Induced Pluripotent Stem Cells)

產(chǎn)品英文名稱：Cellartis® Human iPS Cell Lines

產(chǎn)品中文名稱：Cellartis® 人iPS誘導(dǎo)多能干細胞

Cellartis人iPS細胞（Human iPS Cell Line）產(chǎn)品是達到了工業(yè)客戶使用標準生產(chǎn)的干細胞產(chǎn)品。該產(chǎn)品包括細胞和用于增殖培養(yǎng)的Cellartis DEF-CS Culture System培養(yǎng)體系。iPS細胞已經(jīng)在制品化時完成了對DEF-CS培養(yǎng)體系的適應(yīng)。Cellartis DEF-CS Culture System培養(yǎng)體系是組分明確而且不依賴飼養(yǎng)層的便捷的干細胞培養(yǎng)體系。Cellartis DEF-CS Culture System適合高效率地增殖培養(yǎng)干細胞，并且保持干細胞在增殖過程中幾乎無分化地生長，這使得不需要在大規(guī)模增殖培養(yǎng)過程中進行細胞篩選。因此，Cellartis人iPS細胞（Human iPS Cell Line）產(chǎn)品是一套完整的產(chǎn)品體系，對于科研級別和工業(yè)規(guī)模的需求都適合。

Cellartis人iPS誘導(dǎo)多能干細胞特點

☆細胞系通過使用缺陷型多順反子逆轉(zhuǎn)錄病毒（defective polycistronic retrovirus）技術(shù)重編程人皮膚成纖維細胞以轉(zhuǎn)入Oct-4，SOX2，KLF4和c-Myc

☆細胞系的純度和干細胞特征經(jīng)過廣泛分析，包括解凍后的恢復(fù)，支原體和細菌檢測，干細胞特異性標記物的表達（Oct-4，NANOG，SSEA-3，SSEA-4，TRA-1 -60，TRA-1-81），不表達分化標記（β-3微管蛋白，F(xiàn)OXA2，ASMA）和預(yù)期核型

☆用Cellartis DEF-CS培養(yǎng)系統(tǒng)優(yōu)化培養(yǎng)，試劑盒包括Cellartis DEF-CS 100培養(yǎng)系統(tǒng)

☆適用于所有主要應(yīng)用; 細胞在分化時可以分化形成所有三個胚層的衍生物

Cell lines were created by reprogramming human skin fibroblasts using defective polycistronic retrovirus technology to deliver Oct-4, SOX2, KLF4, and c-Myc

Cell lines are extensively analyzed for purity and stem-cell characteristics, including recovery after thawing, absence of mycoplasma and bacteria, expression of stem cell-specific markers (Oct-4, NANOG, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81), absence of differentiation markers (Beta-3 tubulin, FOXA2, ASMA), and expected Karyotype

Optimized for culture with the Cellartis DEF-CS Culture System

Suitable for all major applications; cells can form derivatives of all three germ layers when differentiated

Kits include the Cellartis DEF-CS 100 Culture System

Cellartis 人iPS誘導(dǎo)多能干細胞參數(shù)

不同貨號對應(yīng)供體年齡性別冷凍代數(shù)和已確認分化能力

1500 1904 520。紅榮微再-客服: 經(jīng)銷商專員

iPS誘導(dǎo)多能干細胞的應(yīng)用

細胞治療、藥物監(jiān)測和疾病模型

Cellartis 人iPS誘導(dǎo)多能干細胞組份

不同供體的iPS細胞系和DEF-CS 100*培養(yǎng)基

*培養(yǎng)基包含基礎(chǔ)培養(yǎng)基、添加劑和包被劑。

保存：細胞 ≤ –150°C，添加劑 –20°C,基礎(chǔ)培養(yǎng)基和包被劑4 °C。

A. Cellartis Human iPS Cell Lines

Cellartis human iPS cell line P11025 (Cat. No. Y00180, not sold separay; sold as a part of Cat.No. Y00185)

Cellartis human iPS cell line P11032 (Cat. No. Y00220, not sold separay; sold as a part of Cat.No. Y00225)

Cellartis human iPS cell line 4 (ChiPSC4) (Cat. No. Y00260, not sold separay; sold as a part of Cat. No. Y00265)

Cellartis human iPS cell line 7 (ChiPSC7) (Cat. No. Y00270, not sold separay; sold as a part of Cat. No. Y00275)

Cellartis human iPS cell line 12 (ChiPSC12) (Cat. No. Y00280, not sold separay; sold as a part of Cat. No. Y00285)

Cellartis human iPS cell line 18 (ChiPSC18) (Cat. No. Y00300, not sold separay; sold as a part of Cat. No. Y00305)

Cellartis human iPS cell line 21 (ChiPSC21) (Cat. No. Y00310, not sold separay; sold as a part of Cat. No. Y00315)

Cellartis human iPS cell line 22 (ChiPSC22) (Cat. No. Y00320, not sold separay; sold as a part of Cat. No. Y00325)

B. Cellartis DEF-CS 100 Culture System

· Cellartis DEF-CS 100 Culture System (Cat. No. Y30020, not sold separay; sold as a part of Cat.Nos. Y00185, Y00225, Y00265, Y00275, Y00285, Y00305, Y00305, and Y00315. A larger 500ml version of this product is sold as Cat. No. Y00310.)

o DEF-CS Basal Medium (100 ml)

o DEF-CS COAT-1 (for 100 ml) (800 µl)

o DEF-CS GF-1 (for 100 ml) (300 µl)

o DEF-CS GF-2 (for 100 ml) (100 µl)

o DEF-CS GF-3 (for 100 ml) (40 µl)

另行準備材料：PBS+TrypLE 選擇酶+TC處理ps表面培養(yǎng)器皿

The following materials are required but not supplied:

· PBS Dulbecco's with Ca2+ & Mg2+ (D-PBS +/+)

· PBS Dulbecco's without Ca2+ or Mg2+ (D-PBS –/–)

· TrypLE Select Enzyme (1X), no phenol red

· Cell culture vessels, Tissue culture treated polystyrene surface

· General cell culture equipment used in cell culture laboratory

參考文獻：

1. de Peppo GM, et al. Osteogenic potential of human mesenchymal stem cells and human embryonic stem cell-derived mesodermal progenitors: a tissue engineering perspective. Tissue Eng Part A.2010 Nov;16(11):3413-3426.

2. Both SK, et al. Differential bone-forming capacity of osteogenic cells from either embryonic stem cells or bone marrow-derived mesenchymal stem cells. J Tissue Eng Regen Med.2011 Mar;5(3):180-190.

3. de Peppo GM, et al. Free-form-fabricated commercially pure Ti and Ti6A14V Porous Scaffolds support the growth of human embryonic stem cell-derived mesodermal progenitors. ScientificWorldJournal. 2012;2012:646417.Epub 2012 Jan 4.

4. Ou Li, et al. Human embryonic stem cell-derived mesenchymal stroma cells(hES-MSCs) engraft in vivo and support hematopoiesis without suppression immune function: implications for off –the shelf ES-MSC therapies. PLOS ONE.2013; 8(1):e55319.

Cellartis 人iPS誘導(dǎo)多能干細胞訂購信息

不同貨號的區(qū)別：iPS細胞供體不同

關(guān)聯(lián)產(chǎn)品

人iPS細胞*培養(yǎng)基

http://www.chem17.com/st321032/Product_29103798.html

華雅再生醫(yī)學(xué)旗艦公司：紅榮微再（上海）生物工程技術(shù)有限公司主營細胞治療和精準醫(yī)療等產(chǎn)品，2018年與TAKARA繼續(xù)合作，授權(quán)代理（上海）其旗下Cellartis干細胞研究制品和Rubicon單細胞文庫構(gòu)建試劑。Cellartis公司位于瑞典，擁有iPS細胞等干細胞分化為肝細胞及臟器細胞的分化誘導(dǎo)技術(shù)和ES細胞，ips細胞，分化細胞等干細胞相關(guān)產(chǎn)品。

手機1500 1904 520 紅榮微再-客服  經(jīng)銷商專員